Customer Services - 01371 851802
Your basket is empty
Select Delivery Region:
Four Seasons

Welcome to the Journal of Dementia Care

Become a member subscriber

Join a community of all professional staff working with people living with dementia

Sign up today

Already a member subscriber?

Hero Homepage

Member subscriber benefits

Member subscriber benefits
  • New: 15% discount on events and books

    Take advantage of the attractive 15% off the price of our books and conferences at any time of the day or night!

  • New: Read JDC online

    Read the current issue of JDC online and print it if you want

  • Receive printed copies of JDC by mail

    Enjoy the only national dementia publication for everyone working with people living with dementia

  • New: Receive the JDC weekly e-newsletter

    Receive a weekly round-up of dementia news carefully edited by JDC editor Mark Ivory

  • New: Keep up to date with industry news

    You can take advantage of our rolling 24-hour, dementia-focused newsfeed on this website.

Become a member subscriber

View Current Issue Contents Page

  • JDC asks...

    JDC asks...

    Many care homes still rely on antipsychotic medication for some people with dementia. But do they have any alternative?

    Read More


News Update

  • Young onset dementia national charity seeks new chair

    Young onset dementia national charity seeks new chair

    22.02.18 YoungDementia UK is looking for a new chair to help establish it as the "primary young onset dementia charity in the UK". Starting in July, the chair of trustees will be appointed for three years initially, providing strategic leadership at a "pivotal moment of national development and growth," as the charity develops a programme of activities to reach out to more people with young onset dementia and give them more support. For more information, contact Tessa Gutteridge at

  • New drug may allay psychosis symptoms but avoid side-effects

    New drug may allay psychosis symptoms but avoid side-effects

    21.02.18 A new drug called Pimavanserin may provide a relatively safe way to alleviate psychosis symptoms in people with dementia when non-pharmacological approaches fail. Findings from Exeter University, published in the journal Lancet Neurology, suggest that Pimavanserin avoids the dangerous side-effects associated with traditional anti-psychotic medications. Professor Clive Ballard, who led the study, said: "It's particularly encouraging that most benefit was seen in those with the most severe psychotic symptoms, as this group is most likely to be prescribed antipsychotics. We are talking about vulnerable elderly, frail people who are suffering terrifying symptoms, being sedated with current antipsychotics even though it's well known that they cause terrible health issues and even death in people with dementia, and have very little benefit. We urgently need to do better by them, and our encouraging results provide hope."

JDC on Twitter

JDC on Facebook